Mediphage Bioceuticals, Inc.
$75,000.00 CAD
- Department
- National Research Council Canada
- Recipient country
- Canada
- Fiscal year
- 2022-2023
- Agreement period
- February 1, 2023 – September 30, 2023
- Reference
- nrc-cnrc:172-2022-2023-Q4-1001542
Published purpose
This project will optimize the ministring DNA™ (msDNA™) production process to improve yield and purity while also making the process more stable, robust, and resistant to supply chain disruption, while also making the materials safer in the eyes of regulatory agencies by eliminating antibiotic usage from upstream production. Additionally, this project will evaluate next generation msDNA™ constructs to improve the therapeutic effectiveness of the drug substance. In summary, the outcomes of this project will improve the msDNA™ product, the production process, and facilitate the smooth and rapid transition to large-scale production to support Mediphage's genetic medicine program.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.